MedImmune Social Media Press Room

PETER GREENLEAF APPOINTED MEDIMMUNE’S NEW PRESIDENT

2010-02-02T14:31:26Z

GAITHERSBURG, MD, February 2, 2010 – MedImmune today announced that Peter Greenleaf has been appointed as the company’s new President, effective immediately. Mr. Greenleaf will report to Tony Zook, who remains responsible for MedImmune on AstraZeneca’s Senior Executive Team.

Since joining the company in 2006, Peter has been a major contributor to the growth of MedImmune. He has overseen the development of the global marketing and portfolio organizations, as well as managing the broader commercial, corporate development and strategy functions. He has also been accountable for MedImmune Ventures, a corporate development investment group. In addition to being a member of the MedImmune Executive Team, Peter has led the cross-functional Brand Management Team and been a member of the Product Development Committee.

Greenleaf stated: “I am very excited about the future of MedImmune – and the role that biologics will play in achieving AstraZeneca’s long term success. I look forward to working closely with my colleagues from across the broader company.”

Prior to MedImmune, Greenleaf was at Centocor, Inc., where he served as franchise vice president, responsible for sales, marketing, strategic planning and business development. Previously, he served in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc. He has a bachelor of science degree from Western Connecticut State University and a master’s degree in business administration from St. Joseph’s University.

About MedImmune

PIVOTAL TRIAL RESULTS FOR MOTAVIZUMAB PUBLISHED IN CURRENT ISSUE OF PEDIATRICS

2010-01-29T19:12:10Z

GAITHERSBURG, MD, January 29, 2010 – MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of Pediatrics. Motavizumab is an investigational monoclonal antibody (MAb) being evaluated by the FDA for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) among infants at high risk.

The phase 3, pivotal trial assessed the safety and RSV hospitalization in 6,635 preterm infants aged six months or younger at enrollment or children aged 24 months or younger with chronic lung disease of prematurity who received either 15 mg/kg palivizumab or motavizumab monthly. Secondary endpoints included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific MALRIs, otitis media, antibiotic use, development of anti-motavizumab antibodies and motavizumab serum concentrations.

In this first head-to-head trial, motavizumab demonstrated non-inferiority, but not superiority, to SynagisÒ (palivizumab), meeting the primary endpoint with a 26 percent relative reduction in RSV hospitalizations versus Synagis (p<0.01 for non-inferiority) due to RSV. Motavizumab also demonstrated superiority compared to Synagis, with a 50 percent relative reduction in RSV lower respiratory tract infections requiring outpatient management (p=0.005), which was one of the secondary endpoints of the trial. Other secondary endpoints were not statistically significant. Adverse events were similar in both groups, although, motavizumab had two percentage points more adverse events reported for the skin compared to Synagis; the majority were non-specific rashes that did not recur or affect dosing.

In November 2008, the FDA issued a complete response letter (CRL) to MedImmune seeking clarification on the motavizumab Biologic License Application (BLA). MedImmune filed its response with the FDA in December 2009 and continues in its ongoing dialogue with the agency.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV.

About Synagis

Synagis is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Synagis was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002. Synagis is currently available in 62 countries.

Synagis® (palivizumab) is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in infants and children at high risk. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis should not be used in patients with a history of a severe allergic reaction to Synagis or its ingredients. Cases of severe allergic reactions such as anaphylaxis and other types of hypersensitivity reactions have been reported with Synagis. These reactions may occur when any dose of Synagis is given, not just the first one. Very low platelet counts may occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Common side effects may include fever, cold-like symptoms (upper respiratory infection) including runny nose and ear infection, and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth or discomfort). In children born with certain types of heart disease, other possible side effects include bluish color of the skin, lips or under fingernails and abnormal heart rhythms. These are not all the possible side effects of Synagis.

For full prescribing information for Synagis, see the company’s website at: www.medimmune.com/products/synagis/index.asp.

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

# # #

MedImmune Announces Winners of First European Cancer Research Abstract Competition

2009-11-30T16:00:03Z

Cambridge, UK, 23 November 2009 – Today MedImmune announced the winners of its European research abstract competition which highlights the work of tomorrow’s budding scientific leaders in cancer research. Students and postdoctoral fellows from across Europe were invited to submit abstracts on cancer research as part of a competition sponsored by MedImmune, AstraZeneca’s global biologics unit that has a research facility in Cambridge, the United Kingdom.

First prize of £2,000 was awarded to Nicole Simonavicius, a PhD student at The Institute of Cancer Research, London, UK for her research into the role of the tumour pericyte receptor endosialin in angiogenesis. “Winning this competition is a great honour. Gaining such positive feedback from leading experts has confirmed my commitment to scientific research,” said Nicole. “I am grateful to MedImmune for giving me the opportunity to present my research – it is encouraging to see a research-focused company supporting the next generation of scientists.”

Second and third prizes of £1,000 and £500 were awarded to Eva Schlecker, a PhD student at The German Cancer Research Centre, Heidelberg, Germany, and Roberta Burden, a scientist at Queen’s University Belfast, Northern Ireland.

“It is encouraging to see the high calibre of scientific research that went into the submissions we received,” said Professor Volker Schirrmacher, one of the competition’s judges and retired Head of the Division of Cellular Immunology at The German Cancer Research Centre, Heidelberg, Germany. “Their research could pave the way for further understanding of tumour microenvironment and could potentially help in the development of new therapies in the fight against cancer.”

“MedImmune is committed to fostering the development of the next generation of leading scientists focused on improving human health. One of our primary objectives at MedImmune is to promote and advance health and science education, and this competition provides us with the opportunity to acknowledge committed and talented researchers pursuing science degrees and postdoctoral research in the field of oncology.” said Klaus Bosslet, Vice President of Research, Oncology, Cambridge. “We were impressed with the standard of work delivered and congratulate all of the ten finalists for getting this far. The students and scientists represented embody the future of exciting cancer research and we at MedImmune are privileged to play a part in their careers by providing some recognition for their hard work.”

The competition was open to graduate students and postdoctoral fellows in Europe with ten finalists shortlisted to present their research to an expert panel of judges including Professor Gillian Murphy, Department of Oncology, University of Cambridge; Professor Volker Schirrmacher, retired Head of the Division of Cellular Immunology at The German Cancer Research Centre, Heidelberg, Germany; and two senior MedImmune representatives. The three winners were announced at the awards ceremony in Cambridge University’s historic Peterhouse College following evaluation of their presentations on the basis of scientific merit, innovation and delivery.

About MedImmune

# # #

MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition

2009-11-17T14:14:58Z

GAITHERSBURG, MD, November 16, 2009 – MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory disease, inflammation and autoimmunity (RIA). Students and postdoctoral fellows from across the country were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, a leading biologics company headquartered in Gaithersburg, Maryland.

The competition’s ten finalists convened today at the company’s headquarters to present their research to an expert panel of MedImmune judges. The three winners were announced at the awards ceremony following the presentations.

First prize of $2,000 was awarded to Eric Boilard, a postdoctoral student of Harvard Medical School and Brigham & Women’s Hospital for his research on the role of platelets in amplifying inflammation in arthritis. “I would like to thank everyone at MedImmune for sponsoring this competition. I am honored to be a winner and grateful for the opportunity to receive such great feedback from renowned individuals on the panel.”

Second and third prizes of $1,000 and $500 were awarded to Irving Allen of University of North Carolina and Kerstin Kiefer of Boston University School of Medicine, respectively.

“We saw some very high-caliber preclinical approaches,” said Anthony J. Coyle, Ph.D., vice president, research and development and head, respiratory, inflammation and autoimmunity research at MedImmune. “Their research could pave the way for further understanding of the mechanism of these diseases, and could potentially help in the development of new therapies.”

“We are committed to investing in future scientists and promoting health and science education,” said Bahija Jallal, Senior Vice President of Research and Development at MedImmune. “We were impressed with today’s presentations, and congratulate all of the ten finalists on their thought-provoking work.”

The competition was open to graduate students and postdoctoral fellows worldwide. The expert panel of judges evaluated the abstracts according to the following criteria: scientific rationale, description of what was done, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

Notes to Editors:

First Place: Harvard Medical School, Brigham & Women’s Hospital postdoctoral student Eric Boilard. The title of his abstract is “Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.”

Second Place: University of North Carolina at Chapel Hill postdoctoral student Irving Allen. The title of his abstract is “NLRX1 is a regulator of the innate immune response to influenza A virus infection.”

Third Place: Boston University School of Medicine postdoctoral student Kerstin Kiefer. The title of her abstract is “The role of TAM receptor tyrosine kinases in B cell activation and differentiation.”

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.

For more information, visit MedImmune’s website at www.medimmune.com.

# # #

MedImmune to Present 4 Abstracts on RSV and Influenza at 47TH Annual IDSA Meeting

2009-10-30T18:36:11Z

PHILADELPHIA, P.A., October 30, 2009 – MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune’s leadership in pediatric health.

“MedImmune is dedicated to conducting ground-breaking research on the prevention of respiratory syncytial virus (RSV) and influenza in children,” said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. “We believe the data being presented at the conference may help advance innovative healthcare solutions for these important causes of respiratory infections in children.”

MedImmune abstracts to be presented at IDSA on RSV include:

Prophylaxis Utilizing Nebulized Motavizumab, a Monoclonal Antibody Against Fusion Protein of Respiratory Syncytial Virus (RSV) Zhang J, et al. Poster Session: October 30, 2009; 12:30 – 2:00 PM; Poster Hall A / Poster # 608

BACKGROUND: Respiratory syncytial virus (RSV) infection is the primary cause of pneumonia and bronchiolitis in young children, and also causes disease in older adults. This study evaluated the prophylactic use of nebulized motavizumab, an investigational anti-RSV humanized monoclonal antibody against RSV fusion protein, in cotton rats. The findings suggest that prophylaxis with nebulized motavizumab may inhibit RSV infection and spread in the lungs and may provide an alternative to the current intramuscular antibody delivery.

MedImmune abstracts to be presented at IDSA on influenza include:

A Postmarketing Evaluation of the Frequency of Use and Safety of Live Attenuated Influenza Vaccine Use in Unapproved Children Less Than 59 Months of Age Tennis P, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1179

BACKGROUND: In September 2007, the approval of live attenuated influenza vaccine (LAIV) was expanded for use in children between 24 and 59 months in age. The vaccine was not approved for use in children younger than 24 months, or for use in children with asthma or recurrent wheezing, or those with altered immunocompetence. This study evaluates the usage and safety of the vaccine in those patient populations younger than 59 months of age that were not in the approved indication. The study found that healthcare providers appear to be complying with the indications for the use of LAIV in children <5 years, and no adverse safety outcomes were detected in the small number of children in unapproved groups who received the vaccine.

Whole Genome Transcriptional Analysis of the Early Immune Responses Induced by Live Attenuated and Inactivated Influenza Vaccines in Young Children Zhu W, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1181

BACKGROUND: This study examined the early genomic immune response to live attenuated and inactivated vaccines in previously unvaccinated children 12 to 35 months of age. Among LAIV recipients, an increase in interferon (a natural anti-viral immune protein) production was seen, which may partly explain previous clinical study observations of LAIV-induced protection against illness in the first 2 weeks after administration.

Influenza-Associated Antibiotic Use in Children Receiving Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine Belshe R, et al. Poster Session: October 31, 2009; 12:30-2:00 PM; Hall A / Poster #1180

BACKGROUND: Influenza illness in children commonly results in the unnecessary use of prescription antibiotics. This analysis evaluated the efficacy of live attenuated influenza vaccine (LAIV) and trivalent inactivated influenza vaccine (TIV) in preventing antibiotic use in children ranging from six months to 17 years in age. Overall, there was less influenza-associated antibiotic use in LAIV recipients due to a lower rate of culture-confirmed influenza with LAIV.

###

Additional information about the 2009 IDSA conference can be found at http://www.idsociety.org/IDSA2009.htm.

About FluMist®

FluMist® (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life- threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than two years of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barre syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk. FluMist should be given to a pregnant woman only if clearly needed.

Most common adverse reactions (occurring in 10 percent or more of individuals receiving FluMist and at a rate at least five percent higher than in those receiving placebo) are runny nose or nasal congestion in recipients of all ages, fever more than 100 degrees F in children two to six years of age, and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete Prescribing Information for FluMist, call 1-877-FLUMIST (1-877-358-6478) or visit http://www.medimmune.com/pdf/products/flumist_pi.pdf for additional information.

About MedImmune, Inc.

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

INTERIM CLINICAL TRIAL RESULTS SHOW MEDIMMUNE’S H1N1 VACCINE HAS SIMILAR SAFETY PROFILE AS SEASONAL VACCINE IN ELIGIBLE CHILDREN AND ADULTS

2009-10-22T19:40:37Z

H1N1 Immunogenicity Profile Also Consistent with Seasonal Vaccine Formulations

GAITHERSBURG, MD, Oct. 22 — MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine. The live attenuated influenza vaccine (LAIV) for the 2009 novel Influenza A (H1N1) virus received approval from the U.S. Food and Drug Administration (FDA) on September 15, 2009.

“MedImmune is pleased to report these findings that demonstrate that the safety profile and immunogenicity of our nasal spray vaccine for the 2009 H1N1 virus is, as expected, similar to our seasonal influenza vaccine,” said Filip Dubovsky, M.D., vice president, clinical development, vaccines. “It is rewarding for all of us at MedImmune to see the vaccine being used to help protect the U.S. population from this novel strain of influenza.”

Two randomized, double-blind, placebo-controlled trials are ongoing in children (2–17 years) and adults (18–49 years) to evaluate the safety, tolerability, and immunogenicity of vaccine. A total of 326 children and 300 adults were randomly assigned to receive 2 doses of 2009 H1N1 LAIV or placebo 28 days apart. Both clinical trials are collecting data following a second dose of the vaccine.

LAIV for 2009 H1N1 is made using the same process as LAIV for seasonal influenza. The safety of the 2009 H1N1 vaccine was evaluated in the same way that the safety of new seasonal LAIV strains is assessed every year. The H1N1 vaccine was also evaluated in children to further establish its safety profile.

In children, the most common side effects following the first dose of vaccine included headache, runny/stuffy nose, and cough. In adults, the most common side effects were headache, runny nose and decreased activity. Symptoms after the second dose were similar but generally occurred at lower rates in both children and adults. No vaccine-related serious adverse events have been reported in children or adults. The local and systemic symptoms observed are consistent with intranasal vaccine virus replication and are similar to those observed with seasonal LAIV. Serum antibody responses to the vaccine in addition to pre-clinical characterization data are also consistent with previously studied formulations of seasonal LAIV, which has been shown in multiple studies to be safe and effective in eligible children and adults 2 to 49 years of age.

LAIV initiates the immune response in the nose, where the virus enters the body and replicates, and is the key to establishing a vaccine response that will help prevent disease if the person later encounters a circulating H1N1 virus. In response to the vaccine, the body develops mucosal immunoglobulin A (IgA), serum immunoglobulin G (IgG), and cellular immunity to help protect the individual from infection from an influenza virus.

Study results have been submitted to and reviewed by authorities at the FDA, the U.S. Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the U.S. Department of Health and Human Services (HHS).

About LAIV

LAIV is different from the injectable influenza vaccine (”flu shot”) in that it contains live vaccine virus strains that are specifically designed to prompt the body to begin mounting a protective response, but weakened so as not to cause the flu. It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection. MedImmune’s seasonal influenza vaccine is currently licensed in the United States, South Korea, and Hong Kong and MedImmune’s H1N1 influenza vaccine is currently licensed in the United States; both are approved for eligible individuals 2 through 49 years of age.

Important Safety and Eligibility Information for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Who may be eligible for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal? Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is a vaccine approved for the prevention of influenza disease caused by pandemic (H1N1) 2009 virus in children, adolescents and adults, from 2-49 years of age. Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal may not protect everyone who gets it. This vaccine is for intranasal administration only. Children 2 through 9 years of age are recommended to receive 2 doses of vaccine approximately 1 month apart; individuals 10 years of age and older are recommended to receive a single dose of vaccine.

Who may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is not right for everyone. This vaccine must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for this vaccine.

The following people may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or may be able to get it only in certain situations: people with asthma or active wheezing, or children less than 5 years of age with recurrent wheezing; people with a history of Guillain-Barré syndrome; people with a weakened immune system; people with long-term medical conditions including heart disease, kidney disease, and metabolic diseases, such as diabetes; and pregnant women.

If a patient falls into one of these groups, a health care provider will decide if Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is right for them.

For Complete Product Information

please visit: http://www.medimmune.com/pdf/products/h1n1_pi.pdf

About MedImmune

The Novel Influenza A (H1N1) project has been funded in whole or in part with the Federal funds from HHS/ASPR, under Contract No. HHSO100200900002I. The opinions expressed herein do not represent opinions or statements made or expressed by the U.S. Department of Health and Human Services.

For more information, visit MedImmune’s website at www.medimmune.com.

MEDIMMUNE TO PRESENT DATA ON RSV AND INFLUENZA AT 2009 AMERICAN ACADEMY OF PEDIATRICS NATIONAL CONFERENCE & EXHIBITION

2009-10-16T18:08:51Z

WASHINGTON, October 16, 2009 – MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company’s growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention.

“With influenza and RSV becoming more widespread this time of year, it remains important to better understand the impact of infectious diseases on pediatric health and the healthcare system, as well as what we can do to prevent illness,” said Alexander A. Zukiwski, M.D., executive vice president and chief medical officer. “The data being presented at the conference build on our extensive foundation of research and help advance innovative solutions for preventing illnesses that negatively impact the health of children.”

MedImmune abstracts to be presented at AAP on RSV include:

“Late Breaking Trial: A Randomized Controlled Trial of RSV Prophylaxis with Motavizumab vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease.”

Feltes, T. et al., Oral Presentation; 9:30 AM – Oct 18, 2009; H2019 Section on Cardiology & Cardiac Surgery Program Washington Convention Center, Room 201

BACKGROUND: Congenital heart disease (CHD) patients are at high risk of complications from RSV lower respiratory infection and may benefit from passive immunoprophylaxis. Motavizumab is an investigational RSV-specific monoclonal antibody that is currently being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This randomized, double-blind, active-controlled clinical trial evaluated the safety and tolerability of motavizumab in children with congenital heart disease – a population at high risk for serious RSV disease. Secondary objectives sought to determine the effect of motavizumab on rates of RSV-related hospitalization and RSV-specific lower respiratory tract infections, as well as describe motavizumab’s pharmacokinetics and immune response.

“Serious Early Childhood Wheezing Following Respiratory Syncytial Virus Lower Respiratory Tract Infection During Infancy Among Preterm Infants”

Romero, JR et al (presenter: Hasan Jafri, MD)[Friday, October 16, 2009; Room 145 (Washington Convention Center)]

BACKGROUND: Prior studies have suggested that RSV infection is associated with the development of recurrent wheezing in early childhood. However, these studies have had limited sample sizes and lacked laboratory confirmation. This retrospective cohort study sought to determine the relationship between medically attended RSV and recurrent wheezing in the third year of life. Charts of nearly 90,000 infants born at 32 weeks gestation or greater were analyzed for evidence of recurring wheezing and RSV infection, and laboratory testing for RSV was confirmed.

“Increased Medical Costs and Use within a Year After Respiratory Syncytial Virus Lower Respiratory Tract Infection Among Commercially-Insured Late-Preterm Infants”

Palmer, L et al (presenter: Lisa Palmer, MD) [Friday, October 16, 2009; Room 145 (Washington Convention Center)]

BACKGROUND: RSV is the leading cause of hospitalization for infants up to the age of one, and is responsible for one of every 13 visits to a pediatrician and one of every 38 emergency room trips for children up to the age of five. This burden on the healthcare system has associated costs. This retrospective cohort study evaluated the total healthcare costs and use of services from infants born between 33 – 36 weeks gestation infected with RSV lower respiratory tract infection (LRI). These late-preterm infants were compared with a control group of infants without RSV LRI, all of whom were commercially insured.

MedImmune abstracts to be presented at AAP on influenza include:

Survey of Physician-Led Influenza Immunization Programs in Schools

Harry F. Hull, M.D., HF Hull & Associates, Oral Presentation

: October 19; 11:45-11:55 AM Session: Council on School Health

BACKGROUND: The American Academy of Pediatrics, American Academy of Family Physicians, and the Advisory Committee on Immunization Practices now recommend annual influenza immunizations for all children aged six months to 18 years. School-located immunization programs (SIPs) may offer an efficient, less costly means to reach large numbers of school-aged children. There have been reports of physician-led SIPs conducted independently from public health departments, but little is known about these programs. This study documented the experience of physician-led SIPs for the benefit of other physicians considering organizing SIPs.

Additional information about the 2009 AAP National Conference & Exhibition can be found at http://www.aap.org/nce/.

About Palivizumab

Palivizumab is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children at high risk. It is given as a shot, usually in the thigh muscle, each month during the RSV season. Children who develop an RSV infection while receiving palivizumab should continue the monthly dosing schedule throughout the season.

Palivizumab should not be used in patients with a history of a severe allergic reaction to palivizumab or its ingredients. Cases of severe allergic reactions such as anaphylaxis and other types of hypersensitivity reactions have been reported with Synagis. These reactions may occur when any dose of Synagis is given, not just the first one. Very low platelet counts may occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Common side effects may include fever, cold-like symptoms (upper respiratory infection) including runny nose and ear infection, and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth or discomfort). In children born with certain types of heart disease, other possible side effects include bluish color of the skin, lips or under fingernails and abnormal heart rhythms. These are not all the possible side effects of Synagis.

For full prescribing information for palivizumab (tradename Synagis^®), see the company’s website at: http://www.medimmune.com/pdf/products/synagis_pi.pdf

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, MedImmune aims to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health.

For more information, visit MedImmune’s website at www.medimmune.com.

MEDIMMUNE HIGHLIGHTS INFLAMMATORY DISEASE PORTFOLIO AT 73RD ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY

2009-10-15T22:58:15Z

GAITHERSBURG, MD, October 15, 2009 – MedImmune today announced that researchers will present data on several inflammatory disease programs at the annual meeting of the American College of Rheumatology, from October 17 to 21, 2009 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

“Through our research into novel disease pathways involved in autoimmune disorders, we continue to fulfill our mission of using scientific excellence to deliver life-changing medicines for patients with rheumatic diseases,” said Anthony Coyle, PhD., vice president, head of respiratory, inflammation, and autoimmune disease research. “Representing some of our most recent progress, we are pleased to share data relevant to the development of new therapies for conditions such as lupus, rheumatoid arthritis, and scleroderma.”

The schedule for MedImmune’s nine posters and two oral presentations at the meeting, starting on Sunday October 17, is as follows:

Relationship Between Disease Activity and Type 1 Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis

In Vitro and In Vivo Properties of MEDI-571, a Human Anti IL-17A Antibody in Development for the Treatment of Patients with Rheumatoid Arthritis

Utilising Assay Systems Relevant to IL-6 Mechanisms in Rheumatoid Arthritis to Demonstrate Efficacy of a Novel Human Anti-IL-6 Antibody, CAT6001

MEDI5117: A Human High Affinity Anti-IL-6 Monoclonal Antibody with Enhanced Serum Half-Life in Development for the Treatment of Inflammation and Rheumatological Diseases

Tissue Plasminogen Activator (tPA) Restores Normal Fibrinolysis / Coagulation Balance in Kidney and Reverses Clinical Score in Skin in a Murine Graft-Versus-Host Disease Model of Scleroderma: Proof of Concept for Therapeutic Fibrinolysis in Scleroderma

Neutralization of Angiopoietin 2 Reduces Disease in Murine Arthritis and Augments Efficacy of Anti-TNF Treatment

Critical Requirement of RAGE for Development of Lung Fibrosis in An Experimental Model of Systemic Sclerosis

Depletion of Inducible Co-Stimulator (ICOS) Bearing T Cells Inhibits Expansion of T Follicular Helper Cells (TFH) and Prevents Disease in a Graft Versus Host Mouse Model of Scleroderma

Autoimmune-Driven Skin Fibrosis: The Critical Requirement for IFNAR1 in An Experimental Model of Systemic Sclerosis

Human S100 Proteins Differentially Regulate Pro-Inflammatory Cytokine Release and Cell Migration

CAM-3001; a Novel Human Monoclonal Antibody against GM-CSFR-á, in Subjects with Rheumatoid Arthritis (RA): Results of a Phi Study

About MedImmune

(Oral Presentation) – Gerd-R Burmester, M.D., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1926– Bo Chen, Ph.D., Tuesday, October 20 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1331 – Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1067– Gianluca Carlesso, Ph.D., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1065–Tracy Delaney, M.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1053– Brian Naiman, MS., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 666 – Timothy Burwell, B.Sc., Monday, October 19 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 1062– Jacques Moisan, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 401–Donna Finch, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 45, Abstract: 587

(Oral Presentation)–Steven Greeberg, Ph.D., Sunday, October 18 at 3:00 p.m. in Room 202 B

– Matthew Sleeman, Ph.D., Sunday, October 18 from 9:00 a.m. – 11:00 a.m. in Hall D, Abstract: 8

For more information, visit MedImmune’s website at www.medimmune.com.

MedImmune Receives Highest Honor from The Gazette of Politics and Business

2009-09-24T16:02:28Z

Gaithersburg, Md. – MedImmune was named by The Gazette of Politics and Business as the top business in the State of Maryland. The list of the 53 top businesses and organizations in the state was released at an awards ceremony held September 23, 2009. It acknowledges the top 53 businesses and organizations in Maryland based on annual revenue, employee growth, product or service innovations, community service efforts, steerage through the economic downturn, and reasons they are good places to work.

“I applaud these exceptional Maryland businesses that are consistently on the leading edge of innovation and doing their part to help through their pro-active community service programs. To make the 53 list is a great accomplishment,” said Cliff Chiet, publisher of The Gazette P&B. MedImmune will be profiled in a special section as part of the September 25, 2009 edition of The Gazette of Politics and Business.

MedImmune was recognized for its exceptional growth, community service programs in health and science, education for young people, and innovative scientific and medical technology. Toni Stiefel, director, corporate responsibility and community affairs, accepted the award for MedImmune and noted, “We are extremely honored to be recognized by the Gazette for doing exactly what we are passionate about—helping patients and our community live better lives. The work our employees do outside of our laboratories and manufacturing sites is as important as the technological advancements that we make inside our facilities.”

About MedImmune

www.medimmune.com.

MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza

2009-09-21T23:46:18Z

GAITHERSBURG, MD, Sept. 21 — MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million. Previous HHS orders for approximately 13 million doses of LAIV for the 2009 H1N1 strain were placed in May and July.

The vaccine received approval from the U.S. Food and Drug Administration (FDA) on Sept. 15 and is indicated for the active immunization of individuals 2-49 years of age against influenza caused by pandemic (H1N1) 2009 virus.

MedImmune’s development of LAIV for this strain of H1N1 began at the end of April, when the company received the novel virus from the U.S. Centers for Disease Control and Prevention (CDC). Enough bulk vaccine to fill all orders placed by HHS has already been manufactured and about 3.4 million doses have been released by the FDA. Distribution will occur at the direction of public health authorities.

“At MedImmune, our mission is to develop and deliver medicines that change lives, and we are proud that our innovative LAIV technology may help protect the public from the threat of 2009 H1N1 influenza,” said Tony Zook, president of MedImmune. “We will continue to work collaboratively with the U.S. government and public health authorities to contribute to the response to this unpredictable infectious disease.”

About LAIV

LAIV is different from the injectable influenza vaccine (“flu shot”) in that it contains live vaccine virus strains that are weakened so as not to cause the flu. It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection. LAIV prompts the body to begin mounting an immune response after the first dose. MedImmune’s influenza vaccines are currently only licensed in the United States.

Important Safety and Eligibility information for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Who may be eligible for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is a vaccine approved for the prevention influenza disease caused by pandemic (H1N1) 2009 virus in children, adolescents and adults, from 2-49 years of age. Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal may not protect everyone who gets it. This vaccine is for intranasal administration only.

Who may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is not right for everyone. This vaccine must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for this vaccine.

If a patient falls into one of these groups, a health care provider will decide if Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is right for them.

What are the most common side effects of Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Most common side effects are based on studies conducted with seasonal trivalent Influenza Vaccine Live, Intranasal manufactured by MedImmune and include runny nose or nasal congestion, sore throat, and fever. For a full list of side effects, please see section 6.1 in the following product information.

For Complete Product Information please visit: http://www.medimmune.com/pdf/products/h1n1_pi.pdf

About MedImmune

###

ATTENTION BROADCASTERS: B-ROLL AVAILABLE